Literature DB >> 11917165

Morphologic and molecular prognostic markers in prostate cancer.

Jeffrey S Ross1, Christine E Sheehan, Eric M Dolen, Bhaskar V S Kallakury.   

Abstract

In this review, a series of traditional morphology-based measurements, relatively well-documented ancillary biomarkers, and emerging molecular assays are evaluated for their relative ability to predict prognosis in prostate cancer. Prognostic factors that have achieved widespread use and are classified as category I by the College of American Pathologists' Solid Tumor Prognostic Factor Consensus Conference are compared with newer tests that are beginning to be used in clinical practice (category II) and emerging molecular-based assays that have yet to be widely validated in the published literature or in clinical trials (category III).

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11917165     DOI： 10.1097/00125480-200203000-00003

Source DB:  PubMed          Journal:  Adv Anat Pathol        ISSN： 1072-4109            Impact factor:   3.875


  8 in total

1.  Bcl-2 as a predictive factor for biochemical recurrence after radical prostatectomy: an interim analysis.

Authors:  In-Chang Cho; Han Soo Chung; Kang Su Cho; Jeong Eun Kim; Jae Young Joung; Ho Kyung Seo; Jinsoo Chung; Weon Seo Park; Eun Kyung Hong; Kang Hyun Lee
Journal:  Cancer Res Treat       Date:  2010-09-30       Impact factor: 4.679

Review 2.  Molecular and genetic prognostic factors of prostate cancer.

Authors:  Arnab Chakravarti; Gary Guotang Zhai
Journal:  World J Urol       Date:  2003-08-09       Impact factor: 4.226

3.  DNA replication regulation protein Mcm7 as a marker of proliferation in prostate cancer.

Authors:  V Padmanabhan; P Callas; G Philips; T D Trainer; B G Beatty
Journal:  J Clin Pathol       Date:  2004-10       Impact factor: 3.411

4.  Antisense MDM2 enhances E2F1-induced apoptosis and the combination sensitizes androgen-sensitive [corrected] and androgen-insensitive [corrected] prostate cancer cells to radiation.

Authors:  Thirupandiyur S Udayakumar; Paul Hachem; Mansoor M Ahmed; Sudhir Agrawal; Alan Pollack
Journal:  Mol Cancer Res       Date:  2008-11       Impact factor: 5.852

5.  Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and chemotherapy.

Authors:  Zhuo Zhang; Mao Li; Hui Wang; Sudhir Agrawal; Ruiwen Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-16       Impact factor: 11.205

Review 6.  Biomarkers for the detection and prognosis of prostate cancer.

Authors:  Javier Hernandez; Edith Canby-Hagino; Ian M Thompson
Journal:  Curr Urol Rep       Date:  2005-05       Impact factor: 2.862

7.  Altholactone Inhibits NF-κB and STAT3 Activation and Induces Reactive Oxygen Species-Mediated Apoptosis in Prostate Cancer DU145 Cells.

Authors:  Chunwa Jiang; Muqaddas Masood; Azhar Rasul; Wei Wei; Ya Wang; Muhammad Ali; Muhammad Mustaqeem; Jiang Li; Xiaomeng Li
Journal:  Molecules       Date:  2017-02-07       Impact factor: 4.411

8.  HSP27/Menin Expression as New Prognostic Serum Biomarkers of Prostate Cancer Aggressiveness Independent of PSA.

Authors:  Asma Bourefis; Hajira Berredjem; Omar Djeffal; Thi Khanh Le; Sophie Giusiano; Palma Rocchi
Journal:  Cancers (Basel)       Date:  2022-09-29       Impact factor: 6.575
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.